SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Matthieu F. Bastide, Wassilios G. Meissner, Barbara Picconi, Stefania Fasano, Pierre-Olivier Fernagut, Michael Feyder, Veronica Francardo, Cristina Alcacer, Yunmin Ding, Riccardo Brambilla, Gilberto Fisone, A. Jon Stoessl, Mathieu Bourdenx, Michel Engeln, Sylvia Navailles, Philippe De Deurwaerdère, Wai Kin D. Ko, Nicola Simola, Micaela Morelli, Laurent Groc, Maria-Cruz Rodriguez, Eugenia V. Gurevich, Maryka Quik, Michele Morari, Manuela Mellone, Fabrizio Gardoni, Elisabetta Tronci, Dominique Guehl, François Tison, Alan R. Crossman, Un Jung Kang, Kathy Steece-Collier, Susan Fox, Manolo Carta, M. Angela Cenci, Erwan Bézard, Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease, Progress in Neurobiology, 2015, 132, 96

    CrossRef

  2. 2
    Zsófia Majláth, László Vécsei, NMDA antagonists as Parkinson’s disease therapy: disseminating the evidence, Neurodegenerative Disease Management, 2014, 4, 1, 23

    CrossRef

  3. 3
    Eva Schaeffer, Andrea Pilotto, Daniela Berg, Pharmacological Strategies for the Management of Levodopa-Induced Dyskinesia in Patients with Parkinson’s Disease, CNS Drugs, 2014, 28, 12, 1155

    CrossRef

  4. 4
    Nicolas Morin, Thérèse Di Paolo, Pharmacological Treatments Inhibiting Levodopa-Induced Dyskinesias in MPTP-Lesioned Monkeys: Brain Glutamate Biochemical Correlates, Frontiers in Neurology, 2014, 5,

    CrossRef

  5. 5
    J. Guridi, R. González-Redondo, J. A. Obeso, Clinical Features, Pathophysiology, and Treatment of Levodopa-Induced Dyskinesias in Parkinson’s Disease, Parkinson's Disease, 2012, 2012, 1

    CrossRef

  6. 6
    Marica Carbone, Susan Duty, Marcus Rattray, Riluzole neuroprotection in a parkinson's disease model involves suppression of reactive astrocytosis but not GLT-1 regulation, BMC Neuroscience, 2012, 13, 1, 38

    CrossRef

  7. 7
    Sukju Gil, Changhwan Park, Jeongeun Lee, Hyunchul Koh, The Roles of Striatal Serotonin and l-Amino-acid Decarboxylase on l-DOPA-induced Dyskinesia in a Hemiparkinsonian Rat Model, Cellular and Molecular Neurobiology, 2010, 30, 6, 817

    CrossRef

  8. 8
    Alessandro Stefani, Mariangela Pierantozzi, Giacomo Koch, Salvatore Galati, Paolo Stanzione, Therapy for dyskinesias in Parkinson’s disease patients, Future Neurology, 2010, 5, 2, 277

    CrossRef

  9. 9
    Bazoumana Ouattara, Samah Belkhir, Marc Morissette, Mehdi Dridi, Pershia Samadi, Laurent Grégoire, Leonard T. Meltzer, Thérèse Di Paolo, Implication of NMDA Receptors in the Antidyskinetic Activity of Cabergoline, CI-1041, and Ro 61-8048 in MPTP Monkeys with Levodopa-induced Dyskinesias, Journal of Molecular Neuroscience, 2009, 38, 2, 128

    CrossRef

  10. 10
    Peter Jenner, Preventing and controlling dyskinesia in Parkinson's disease—A view of current knowledge and future opportunities, Movement Disorders, 2008, 23, S3
  11. 11
    Christopher Pittenger, Vladimir Coric, Mounira Banasr, Michael Bloch, John H Krystal, Gerard Sanacora, Riluzole in the Treatment of Mood and Anxiety Disorders, CNS Drugs, 2008, 22, 9, 761

    CrossRef

  12. You have free access to this content12
    Tetsuya Takahashi, Tetsuhito Murata, Yuji Wada, Successful treatment of blepharospasm with tandospirone, a 5-HT1A partial agonist: A case report, Movement Disorders, 2008, 23, 1
  13. 13
    Susan H. Fox, Jonathan M. Brotchie, Non-Dopaminergic Approaches to the Treatment of Parkinson's Disease,